Unlearn
CA - San FranciscoBiotechnology
Focus: Unlearn is a San Francisco-based biotechnology company specializing in machine-learning technology that creates digital twins of patients for clinical trials. The company operates at the intersection of AI and drug development, focusing on neurology applications.
Profile data last refreshed 6h ago · AI intelligence enriched 3w ago
Open Jobs
5+2 this month
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Should You Work at Unlearn?
AI assessmentBest suited for risk-tolerant technologists and product leaders betting on AI-driven clinical trial transformation with an emerging-stage company.
Why Work Here
- Ground-floor opportunity in the rapidly expanding in silico clinical trials market, valued at $8.94B by 2035 with a 15.2% CAGR.
- Active partnerships with major pharma (Acumen Pharmaceuticals) and biotech (VectorY Therapeutics, CHDI Foundation) validating the platform across Alzheimer's, Huntington's, and ALS.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Unlearn
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.